Ono Pharmaceutical And Astellas Launch Osteoporosis Drug
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Ono Pharmaceutical and Tokyo-based Astellas April 7 launched osteoporosis drug RECALBON/Boneteo (minodronic acid) in Japan. Jointly developed by the two, the treatment obtained Japanese approval Jan. 21. The side effects include stomach and abdominal discomfort, abdominal pain, reduced blood calcium and gastritis. Severe side effects include duodenal and gastric ulcers. (Click here for more - Japanese language
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.